The aim of this systematic review and meta-analysis was to investigate the impact of early
sodium-glucose cotransporter-2 (SGLT2) initiation on long-term cardiovascular outcomes …

After acute myocardial infarction, patients are at increased risk for adverse outcomes,
including heart failure and death. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have …

Background Patients who had acute myocardial infarction are at high risk of negative
cardiac outcomes and previous SGLT2i landmark trials excluded these patients. It therefore …

We aimed to assess the efficacy and safety of sodium-glucose cotransporter-2 inhibitors
(SGLT2i) versus placebo, initiated within the hospitalization period, in addition to habitual …

The evidence for sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the treatment of type
2 diabetes or chronic heart failure was sufficient but lacking in acute coronary syndrome …

Introduction Sodium-glucose cotransporter-2 (SGLT2) inhibitors are integral in treating
patients with heart failure, regardless of the existence of diabetes mellitus. In light of their …

Since there is no specific recommendation of sodium‐glucose cotransporter‐2 (SGLT‐2)
inhibitors in acute myocardial infarction (MI), this systematic review and meta‐analysis was …

Background Acute coronary syndrome (ACS) remains the leading cause of death and
disability worldwide, especially when combined with type 2 diabetes mellitus (T2DM). Many …

Background Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular
(CV) outcomes in patients with or without Type 2 diabetes and heart failure (HF). However …

Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce
cardiovascular complications of type-2 diabetes mellitus. However, the beneficial effects of …